Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034

List of Tables

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market through 2034.

GlobalData estimated that drug sales for PAH in 2024 were approximately $7.65 billion across the 7MM. With an estimated $5.83 billion in drug sales in 2024, the US dominated the PAH market, contributing 76.3% of the sales in the 7MM. This high market share is primarily due to the large PAH prevalent population and high price of branded drugs in the US compared to the 5EU and Japan. GlobalData anticipates that the PAH market will grow to be worth approximately $9.35 billion by 2034, at a compound annual growth rate (CAGR) of 2.0%. The US is expected to maintain its position as the market leader in 2034.

The major drivers of growth in the PAH market during the forecast period include the following:

The number of total prevalent cases of PAH in the US, France, and the UK is expected to increase during the forecast period in line with population growth, therefore increasing the total addressable patient population. As populations age and diagnostic awareness improves, more patients are being identified and treated for PAH. Expanded screening in high-risk groups and longer patient survival are contributing to a growing prevalence pool, particularly in the US.
Increased use of combination therapy following the positive outcomes from the AMBITION trial has boosted PAH sales due to higher treatment costs of drug combinations. The AMBITION trial established the superiority of initial dual therapy over monotherapy, prompting widespread adoption of endothelin receptor antagonist (ERA) + phosphodiesterase-5 inhibitor (PDE5i) combinations. As dual and triple regimens become standard, the use of multiple drugs raises treatment costs and overall market value.
The increased usage of Merck's first-in-class Winrevair (sotatercept) and launch of pipeline therapies including Liquidia Corp's Yutrepia (treprostinil) and Tenax Therapeutics' imatinib will boost PAH sales. Winrevair is the first approved disease-modifying agent for PAH and is expected to see broad uptake across patient segments. New launches like Yutrepia, with improved inhaled delivery, and oral imatinib, targeting vascular remodeling, will expand treatment options and support continued market growth.
The major barriers to growth in the PAH market during the forecast period will include the following:
Low disease awareness among patients and physicians will lead to a lower disease diagnosis rate and delayed diagnosis. Many early PAH symptoms are nonspecific and often misattributed to more common conditions, resulting in under-referral and diagnostic delays. Limited recognition of risk factors and insufficient screening outside of specialist centers continue to hinder timely treatment initiation.

Scope

Overview of pulmonary arterial hypertension, including epidemiology, symptoms, diagnosis, and disease management.
Annualized pulmonary arterial hypertension therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the pulmonary arterial hypertension therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for pulmonary arterial hypertension treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global pulmonary arterial hypertension therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM PAH therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PAH therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Product Code: GDHC318PIDR-7M

1 Pulmonary Arterial Hypertension: Executive Summary
1.1 Pulmonary arterial hypertension therapeutics market will grow to $9.34 billion by 2034
1.2 Winrevair is reshaping the PAH treatment landscape following its commercial launch
1.3 Persistent unmet needs underscore opportunity for innovation across the PAH landscape
1.4 Late-stage pipeline advances offer strategic additions across the PAH treatment landscape
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
3.2 Classification or staging systems
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed incident cases and diagnosed prevalent cases of PAH
- 4.4.4 7MM
- 4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PAH by NYHA functional class
- 4.4.6 US
- 4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PAH by comorbidity
- 4.4.8 US
4.5 Epidemiological forecast for PAH (2024-34)
- 4.5.1 Diagnosed incident cases of PAH
- 4.5.2 Age-specific diagnosed incident cases of PAH
- 4.5.3 Sex-specific diagnosed incident cases of PAH
- 4.5.4 Diagnosed prevalent cases of PAH
- 4.5.5 Age-specific diagnosed prevalent cases of PAH
- 4.5.6 Sex-specific diagnosed prevalent cases of PAH
- 4.5.7 Diagnosed prevalent cases of PAH by NYHA functional class
- 4.5.8 Diagnosed prevalent cases of PAH by comorbidity
4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 Limitations of the analysis
- 4.6.3 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 US disease management
5.3 5EU disease management
5.4 Japan disease management
5.5 KOL insights on disease management
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Improved physician awareness and earlier diagnosis
7.3 Improved therapy convenience and reduced side effects
7.4 Disease-modifying therapies
7.5 Improved clinical trial design
8 R&D Strategies
8.1 Overview
- 8.1.1 Disease-modifying mechanisms and novel targets
- 8.1.2 Innovations in drug delivery and combination therapy
- 8.1.3 Strategic collaborations and targeted development
8.2 Clinical trials design
- 8.2.1 Advancements in PAH endpoints
- 8.2.2 Patient population selection
- 8.2.3 Use of surrogate biomarkers
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
- 13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
- 13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Vice President of Disease Intelligence and Epidemiology
- 13.6.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
About GlobalData
Contact Us

Product Code: GDHC318PIDR-7M

List of Table

List of Tables

Table 1: PAH: key metrics in the 7MM
Table 2: NYHA/WHO functional class (FC)
Table 3: Risk factors and comorbidities for PAH
Table 4: Treatment guidelines for PAH
Table 5: Top 10 deals by value, 2020-25
Table 6: PAH market - global drivers and barriers, 2024-34
Table 7: Key events impacting sales for PAH in the US, 2024-34
Table 8: PAH market - drivers and barriers in the US, 2024-34
Table 9: Key events impacting sales for PAH in the 5EU, 2024-34
Table 10: PAH market - drivers and barriers in the 5EU, 2024-34
Table 11: Key events impacting sales for PAH in Japan, 2024-34
Table 12: PAH market - drivers and barriers in Japan, 2024-34
Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figure

List of Figures

Figure 1: Global sales forecast by country for PAH in 2024 and 2034
Figure 2: Analysis of the company portfolio gap in PAH during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of PAH during the forecast period
Figure 4: Target pathways of the currently marketed drugs for PAH
Figure 5: 7MM, diagnosed incidence of PAH (cases per 100,000 population), both sexes, all ages, 2024
Figure 6: 7MM, diagnosed prevalence of PAH (%), both sexes, all ages, 2024
Figure 7: 7MM, sources used and not used to forecast the diagnosed incident cases of PAH
Figure 8: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PAH
Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of PAH by NYHA functional classes in the 7MM
Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of PAH by comorbidities (CTD, CHD, and scleroderma)
Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of PAH by comorbidities (diabetes, COPD, and PH)
Figure 12: 7MM, diagnosed incident cases of PAH, N, both sexes, all ages, 2024
Figure 13: 7MM, diagnosed incident cases of PAH by age, N, women, 2024
Figure 14: 7MM, sex-specific diagnosed incident cases of PAH, N, all ages, 2024
Figure 15: 7MM, diagnosed prevalent cases of PAH, N, both sexes, all ages, 2024
Figure 16: 7MM, diagnosed prevalent cases of PAH by age, N, both sexes, 2024
Figure 17: 7MM, sex-specific diagnosed prevalent cases of PAH, N, all ages, 2024
Figure 18: 7MM, diagnosed prevalent cases of PAH by NYHA functional class, N, both sexes, all ages, 2024
Figure 19: 7MM, diagnosed prevalent cases of PAH by comorbidity, N, both sexes, all ages, 2024
Figure 20: Diagnostic approach to PAH
Figure 21: Unmet needs and opportunities in PAH
Figure 22: Overview of the development pipeline in PAH
Figure 23: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for PAH in the 7MM during the forecast period
Figure 24: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care (SOC), Opsumit
Figure 25: Analysis of the company portfolio gap in PAH during the forecast period
Figure 26: Global (7MM) sales forecast by country for PAH in 2024 and 2034
Figure 27: Sales forecast by class for PAH in the US in 2024 and 2034
Figure 28: Sales forecast by class for PAH in the 5EU in 2024 and 2034
Figure 29: Sales forecast by class for PAH in Japan in 2024 and 2034

Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034

Description

Table of Contents

List of Tables

Scope

Reasons to Buy

Table of Contents

Table of Contents

List of Table

List of Tables

List of Figure

List of Figures